<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870688</url>
  </required_header>
  <id_info>
    <org_study_id>VPA 044/K</org_study_id>
    <nct_id>NCT00870688</nct_id>
  </id_info>
  <brief_title>Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening</brief_title>
  <official_title>Non Interventional Trial of Valproate Sustained Release Minitablets Once Daily in the Evening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Desitin Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Desitin Arzneimittel GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Valproate is the first line therapy in primary generalized seizures. The applied drug
      contains sodium valproate in sustained release minitablets. As a multiple unit dosage form
      these can be easily swallowed and taken independent from meals.

      A simple dosage scheme like valproate sustained release minitablets once daily in the evening
      should improve the compliance and likely the seizure situation of the patients. The data of
      this non interventional trial were directly extracted from the physician's electronic patient
      database. The observational period was 7 weeks compared to a retrospective period 7 weeks
      before start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number of Seizures After Conversion To Valproate Retard Minitablets Once Daily</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seizures Within 7 Weeks</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Data About Efficacy, Safety and Compliance</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>epilepsy patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium valproate</intervention_name>
    <description>valproate sustained release minitablets, once daily.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Orfiril (R) long</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        community sample outpatients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age of 12 years and above

          -  epilepsy patients

          -  indication to initiation / conversion to valproate sustained release minitablets once
             daily

        Exclusion Criteria:

          -  contraindication to valproate use

          -  no indication for conversion to valproate sustained release minitablets once daily
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <results_first_submitted>January 9, 2009</results_first_submitted>
  <results_first_submitted_qc>March 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2009</results_first_posted>
  <last_update_submitted>May 19, 2009</last_update_submitted>
  <last_update_submitted_qc>May 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Karin Lohmueller</name_title>
    <organization>Desitin Arzneimittel GmbH</organization>
  </responsible_party>
  <keyword>valproate</keyword>
  <keyword>epilepsy</keyword>
  <keyword>compliance</keyword>
  <keyword>sustained released minitablet</keyword>
  <keyword>Orfiril long</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In total 82 patients were included in this trial. The patients were naive or changed from another antiepileptic or valproate preparation to valproate sustained release minitablets once daily in the evening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sodium Valproate</title>
          <description>Epilepsy patients receive valproate sustained release minitablets, once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death, Unrelated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Granules in the Stools</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sodium Valproate</title>
          <description>Epilepsy patients receive valproate sustained release minitablets, once daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Seizures After Conversion To Valproate Retard Minitablets Once Daily</title>
        <time_frame>7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Data About Efficacy, Safety and Compliance</title>
        <time_frame>7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seizures Within 7 Weeks</title>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Valproate</title>
            <description>Epilepsy patients receive valproate sustained release minitablets, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seizures Within 7 Weeks</title>
          <units>seizures</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lohmueller</name_or_title>
      <organization>Desitin</organization>
      <phone>0049(0)40-59101 ext 373</phone>
      <email>lohmueller@desitin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

